Rearrangements of the Mixed Lineage Leukemia (MLL/KMT2A) gene are present in approximately 10% of acute leukemias and characteristically define disease with poor outcome. Driven by the unmet need to develop better therapies for KMT2A-rearranged leukemia. we previously discovered that the novel anti-cancer agent. curaxin CBL0137. https://foldlyers.shop/product-category/inkjet-original-inks/